Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients

In Vivo

Volumn 22, Issue 6, 2008, Pages 831-836

  Stoelting, Stephanie ^a   Trefzer, Tanja ^a   Kisro, Jens ^a   Steinke, A ^a   Wagner, Thomas ^a   Peters, Stefan O ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cancer chemotherapy; Endothelial progenitor cells; Metronomic chemotherapy

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; CELECOXIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PREDNISOLONE; RITUXIMAB; TROFOSFAMIDE; VASCULOTROPIN RECEPTOR 2; VINCRISTINE;

ADJUVANT THERAPY; ADULT; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD CHEMISTRY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL COUNT; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG CANCER; MALE; MIGRATION INHIBITION; MONONUCLEAR CELL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PROTEIN BLOOD LEVEL; SARCOMA; STEM CELL MOBILIZATION;

EID: 57849163665     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hurwitz H: Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4(Suppl 2): 62-68, 2004.
2. Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, Badve S, Storniolo A, Goulet R and Sledge GW Jr: Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 89(2): 187-197, 2005.
3. Davidoff AM, Ng CY, Brown P, Leary MA, Spurbeck WW, Zhou J, Horwitz E, Vanin EF and Nienhuis AW: Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 7(9): 2870-2879, 2001.
4. Koizumi K, Tsutsumi Y, Kamada H, Yoshioka Y, Watanabe M, Yamamoto Y, Okamoto T, Mukai Y, Nakagawa S, Tani Y and Mayumi T: Incorporation of adult organ-derived endothelial cells into tumor blood vessel. Biochem Biophys Res Conunun 306(1): 219-224, 2003.
5. Stoelting S, Heinze G, Wagner T and Peters SO: High levels of bone marrow derived endothelial cells in murine WEHI and JC tumors. Anticancer Res 28(2A): 771-778, 2008.
6. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G and Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302): 964-967, 2004.
7. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schäfer B, Hossfeld DK and Fiedler W: In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95(10): 3106-3112, 2000.
8. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, Bhavsar JK, Yoder MC, Haneline LS and Ingram DA: Human CD 34+ AC133+ VEGF-R2+ cells are not endothelial progenitor cells but distinct, primitive hematopoetic progenitors. Exp Hematol 35: 1109-1118, 2007.
9. Hristov M, Erl W and Weber PC: Endothelial progenitor cells: isolation and characterization. Trends Cardiovasc Med 13(5): 201-206, 2003.
10. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S and Zeiher AM: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111(22): 2981-2987, 2005.
11. Machein MR, Renninger S, de Lima-Hahn E and Plate KH: Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 13(4): 582-597, 2003.
12. Zentilin L, Tafuro S, Zacchigna S, Arsic N, Pattarini L, Sinigaglia M and Giacca M: Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 107(9): 3546-3554, 2006.
13. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63(15): 4342-4346, 2003.
14. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7): 1878-1886, 2000.
15. Gately S and Kerbel R: Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37: 179-192, 2003.
16. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F and Crump M: High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 12(17): 5190-5198, 2006.
17. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT and Fahey TJ III: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59(5): 987-990, 1999.
18. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60(5): 1306-1311, 2000.
19. Colleselli D, Bijuklic K, Mosheimer BA and Kaehler CM: Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation. Exp Cell Res 312(15): 2933-2941, 2006.
20. Helsing MD: Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study. Eur J Cancer 33(3): 500-502, 1997.
21. Schmidt-Sandte W, Dageforde J, Klapdor R, Wagner T and Wiedemann GJ: Trofosfamide in patients with pancreatic cancer. Anticancer Res 19(4A): 2485-2487, 1999.
22. Klink T, Bela C, Stoelting S, Peters SO, Broll R and Wagner T: Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. J Cancer Res Clin Oncol 132(10): 643-652, 2006.
23. Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6): 423-436, 2004.
24. Furstenberger G, von Moos R and Lucas R: Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94(4): 524-531, 2006.
25. Senger DR, Perruzzi CA, Feder J and Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46(11): 5629-5632, 1986.
26. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G and Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13(1): 73-80, 2002.
27. Chen J, De S, Brainard J and Byzova TV: Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes 11(1): 1-11, 2004.
28. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF and Detmar M: VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201(7): 1089-1099, 2005.
29. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M and Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85(3): 221-228, 2005.
30. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J and Heymach JV: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11(9): 3514-3522, 2005.
31. Wu S, Ko YS, Teng MS, Ko YL, Hsu LA, Hsueh C, Chou YY, Liew CC and Lee YS: Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol 34(12): 1595-1607, 2002.
32. Murata T, Yamawaki H, Yoshimoto R, Hori M, Sato K, Ozaki H and Karaki H: Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. Life Sci 69(22): 2685-2695, 2001.
33. Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn H-J, Hamacher J and Boneberg EM: Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. B J Cancer 94: 524-531, 2006.